Skip to main content
SpringerPlus

Table 4 Univariate analysis of the serum marker concentrations in relation to PFS and OS

From: Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

   

Progression-free survival

Overall survival

Univariate cox analysis

Markers

Levels

N

Me a (95% CI)

p b

Me a (95% CI)

p b

Progression

Death

HR

95% CI

p

HR

95% CI

p

CEA

<5

11

2.8(1.9 – 3.7)

 

4.4(2.7 – 6.1)

 

1.00

  

1.00

  
 

≥5

24

2.8(1.2 – 4.3)

0.155

10.2(5.9 – 14.5)

<0.001

0.58

0.3 – 1.2

0.161

0.23

0.9 – 0.6

0.001

CYFRA 21-1

<3.3

10

3.2(0.0 – 7.8)

 

15.0(0.0 – 31.9)

 

1.00

  

1.00

  
 

≥3.3

25

2.8(2.5 – 3.0)

0.317

6.5(4.3 – 8.6)

0.056

1.51

0.67 – 0.38

0.321

2.34

0.95 – 6.0

0.064

SCC

<1.5

29

2.8(2.0 – 3.7)

 

7.7(3.7 – 11.7)

 

1.00

  

1.00

  
 

≥1.5

6

2.7(2.0 – 3.3)

0.500

6.5(4.7 – 8.3)

0.184

1.36

0.55 – 3.36

0.503

1.87

0.73 – 4.76

0.192

sEGFR

<56.87

20

2.4(1.9 – 2.9)

 

4.2(0.6 – 7.8)

 

1.00

  

1.00

  
 

≥56.87

24

3.2(0.6 – 5.8)

0.051

9.5(5.3 – 13.6)

0.016

0.53

0.3 – 1.0

0.055

0.43

0.21 – 0.87

0.019

EGF

<713.59

22

3.8(1.9 – 5.6)

 

7.4(3.2 – 11.6)

 

1.00

  

1.00

  
 

≥713.59

23

2.6(2.0 – 3.2)

0.405

5.1(4.8 – 5.4)

0.488

1.30

0.7 – 2.4

0.408

1.26

0.7 – 2.4

0.490

TGF-α

<21.81

24

2.3(1.5 – 3.1)

 

5.1(1.5 – 8.7)

 

1.00

  

1.00

  
 

≥21.81

16

2.8(1.8 – 3.7)

0.570

7.7(3.0 – 12.4)

0.732

0.82

0.4 – 1.6

0.572

0.88

0.42 – 1.85

0.733

HB-EGF

<171

14

2.3(0.6 – 4.0)

 

5.1(1.5 – 8.6)

 

1.00

  

1.00

  
 

≥171

10

3.1(1.5 – 4.7)

0.256

15.0(0.0 – 33.0)

0.093

0.60

0.3 – 1.5

0.262

0.42

0.15 – 1.2

0.104

  1. Abbreviations: Me Median, HR Hazard Ratio, CI Confidence interval.
  2. aMonths; bp value calculated using the Log-Rank test.
Back to article page